A study to evaluate whether the results of second line sunitinib therapy related to duration of response of first line imatinib in patients with advanced gastrointestinal stromal tumors (GIST).

Trial Profile

A study to evaluate whether the results of second line sunitinib therapy related to duration of response of first line imatinib in patients with advanced gastrointestinal stromal tumors (GIST).

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2015

At a glance

  • Drugs Sunitinib (Primary) ; Imatinib
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Sep 2015 Status changed from not stated to completed.
    • 20 Jul 2015 New trial record
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top